End of 2022 year message from the CEO
Hi everyone, Looking back on what we have achieved this year, first and foremost, I am incredibly proud of our team.
Written by Aiforia
Introducing Aiforia Education
Aiforia is excited to present the newly rebranded Aiforia Education, formerly known as Aiforia Hub for Education. What is Aiforia Education? ...
Written by Aiforia
Aurora mScope partners with Aiforia to Bring Integrated AI and Image Management Systems to Pathologists
With this integration, pathology departments can utilize Aiforia’s clinical grade, CE-IVD marked AI models or ones built using Aiforia Create, and ...
Written by Aiforia
June 9, 2022
Aiforia makes key advancement towards end-to-end clinical pathology workflow solution with the release of its CE-IVD marked Aiforia® Clinical Suite Viewer
Aiforia Technologies Plc is thrilled to announce it received CE-IVD marking for the Aiforia® Clinical Suite Viewer, a cloud-based platform enabling a holistic approach to cancer diagnostics and prognostics through the viewing of whole slide digital images of human histopathological samples and deep learning AI produced results along with their seamless reporting. The Aiforia viewer provides ...
Written by Aiforia
May 27, 2022
Aiforia releases another CE-IVD marked clinical AI Model — expanding its diagnostic pathology offering to prostate cancer
This latest regulatory certification brings Aiforia’s portfolio of AI-powered diagnostic tools to a total of 5 CE-IVD marked clinical AI models for breast, lung, and now prostate cancer — the most commonly occurring cancer in men. According to the World Cancer Research Fund, more than 1.4 million new cases of prostate cancer were diagnosed in 2020. Both pathologists and patients deserve reliable ...
Written by Aiforia
May 25, 2022
Aiforia adds fourth CE-IVD marked clinical AI Model to its rapidly expanding portfolio of novel tools for cancer diagnostics
Aiforia is providing a uniquely comprehensive approach to breast cancer diagnostics as the majority of cases express ER and/or PR. Therefore, the two are considered to be the most significant biomarkers involved in the evaluation of breast cancer.
Written by Aiforia